SciClone Pharmaceuticals Inc

SciClone Pharmaceuticals — Proxy Contest (February 2009)

35 slides from SciClone Pharmaceuticals's proxy contest presentation, Feb 9, 2009

  1. Slide 1: Global Strategies for Life-Enhancing Drugs

    Exhibit 99.2 Global Strategies for Life-Enhancing Drugs Corporate Presentation February 9, 2009

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements regarding the business, products and financial results of SciClone Pharmaceuticals, Inc. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,

  3. Slide 3: Important Information/ Solicitation Participants Legend

    Important Information/ Solicitation Participants Legend SciClone Pharmaceuticals, Inc. will file a proxy statement in connection with its 2009 annual meeting of stockholders and advises its stockholders to read that proxy statement when it becomes available because it will contain important informat

  4. Slide 4: Our Company Today

    Our Company Today Company Overview • Investment Opportunity • Pipeline • Strategy and Business Structure Product Overview • ZADAXIN ® • DC Bead • RP101 • SCV-07 Looking Forward • Milestones • Investment Opportunity TM

  5. Slide 5: Company Overview

    Company Overview

  6. Slide 6: Investment Opportunity

    Investment Opportunity • Profitability-Driven Enterprise • Solid global sales growth drives sustainable profitability • 2008 revenues: $54 M (unaudited); 46% increase* • 2009 guidance: $60-$62 M revenues; $0.00 - $0.02 EPS • Revenue growth + tight expense management = positive cash flow and EPS • In

  7. Slide 7: Slide 7

  8. Slide 8: ‘ae.

    ‘ae.

  9. Slide 9: Slide 9

  10. Slide 10: Slide 10

  11. Slide 11: Slide 11

  12. Slide 12: Slide 12

  13. Slide 13: Slide 13

  14. Slide 14: Business Update

    Business Update

  15. Slide 15: Growth Opportunity: SciClone in China

    Growth Opportunity: SciClone in China Our Position • Longstanding presence, ZADAXIN launched in 1996 • SPIL China 2008 sales >$50 million** (unaudited) • Sales: Offices in Beijing, Shanghai, Guangzhou, Hong Kong • >160-strong sales organization covers > 500 hospitals • Highly trained, highly product

  16. Slide 16: Revenues and EPS

    Revenues and EPS $.0 $10.0 $20.0 $30.0 $40.0 $50.0 $60.0 $70.0 2005 2006 2007 2008 2009 E Revenue ($M) SciClone Consolidated; 2008 revenues - unaudited * 2006 EPS do not include $8M settlement received that year 2005-2008 CAGR: 25% EPS: ($.17) ($.16)* ($.22) TBA $0.00 - $0.02

  17. Slide 17: Product Overview

    Product Overview

  18. Slide 18: Slide 18

  19. Slide 19: SciClone

    SciClone ZADAXIN® HBVIHCY & Other Indications China, Russia & >30 other countries Malignant Melanoga DC Bead™ Diversity of target markets, disease [@imercn os ru i. = expected 1HO9 indications, and product maturity RP101 . Parcreaiic Cane reduces risk SCV07 Oral Mucositis in Head & Neck Cancer Globa

  20. Slide 20: ZADAXIN (thymalfasin): Immunomodulator for Malignant Melanoma

    ZADAXIN (thymalfasin): Immunomodulator for Malignant Melanoma Description Commercial Opportunity Development Strategy Development Status • Synthetic thymosin alpha 1 (peptide produced naturally by thymus gland) • Stimulates multiple innate and adaptive immune and direct antiviral responses • $200M w

  21. Slide 21: Thymalfasin's Dual Mechanism of Action

    Thymalfasin’s Dual Mechanism of Action

  22. Slide 22: Positive Phase Tumor Response

    Positive Phase 2 Tumor Response Source: SciClone Pharmaceuticals and Sigma-Tau, ASCO, June 2007. Primary endpoint: Overall Tumor Response (Complete Response + Partial Response) 4.1% 9.0% 0% 1% 2% 3% 4% 5% 6% 7% 8% 9% 10% DTIC + IFN (Control) Total Thymalfasin

  23. Slide 23: Thymalfasin Melanoma: Survival Data

    Thymalfasin Melanoma: Survival Data Phase 2 Results Subset Analysis of LDH 1.2 ULN Patients n= Median Survival P= Median Progression Free Survival P= DTIC + IFN (control) 9.4 months 1.9 months DTIC + IFN thymalfasin 6.4mg 12.7 months 0.049 2.6 months 0.050 All thymalfasin arms 12.6 months 0.034 2.6

  24. Slide 24: DC Bead: Targeting Liver Cancer in China

    DC Bead: Targeting Liver Cancer in China Description Commercial Opportunity Development Status Future Plans • Embolic agent, delivers chemotherapy drugs • Microscopic beads with dual anti-tumor effects • Deliver doxorubicin, potentially other chemotherapy agents directly to tumor • Market-specific u

  25. Slide 25: RP101: Phase 2 Chemotherapy Enhancer

    RP101: Phase 2 Chemotherapy Enhancer Description Commercial Opportunity Development Strategy Development Status Future Plans • Chemosensitizing agent: prevents tumor resistance to chemotherapy; orally delivered • $350 M* market opportunity as an additive pancreatic cancer therapy • 37,680 new cases,

  26. Slide 26: RP101: Blocks Resistance to Chemotherapy

    RP101: Blocks Resistance to Chemotherapy

  27. Slide 27: SCV-07: Phase 2 Oral Mucositis and HCV Opportunities

    SCV-07: Phase 2 Oral Mucositis and HCV Opportunities Description Commercial Opportunity Development Strategy Future Development • Subcutaneously administered small molecule; also orally available • Stimulates immune system, increases T-helper cells (Th1 response specifically) • Oral Mucositis: Vast

  28. Slide 28: SCV-07: Multiple Immune Modulating Effects

    SCV-07: Multiple Immune Modulating Effects

  29. Slide 29: SciClone

    SciClone Pt Dwwnment Feet | Poses | ees |e ZADAXIN® HBVIHCY & Other Indications China, Russia & >30 other countries Malignant Melangg DC Bead™ Diversity of target markets, disease [ieivemant ind ° expected 1HO9 ications, Tare | prod ct maturity pecte: RP101 Pancreatic Can| reduces risk SCVO7 Oral Mu

  30. Slide 30: What's Ahead

    What’s Ahead

  31. Slide 31: Upcoming Milestones

    Upcoming Milestones Milestone Timeline Ongoing Acquire additional product for Chinese market 1H10 RP101 Phase 2 unblinding 2008 guidance: $52-$54 revenues; YE cash >$20 M 2009 Launch DC Bead – China 2009 Phase 3 Thymalfasin Malignant Melanoma Trial; Ongoing partnering discussions 1H09 Complete enrol

  32. Slide 32: Selected Consolidated Financials

    Selected Consolidated Financials FY Ended 12/31 (US$M) 2008 Guidance 2009 >$20 % Change $60-$62 Guidance 2009 Revenues FY Ended 12/31 (US$M) 2008 Revenues Guidance EPS 2009 Cash & Equivalents >$27 (Unaudited) 46% $54 (Unaudited) $0.00 - $0.02

  33. Slide 33: Investment Opportunity

    Investment Opportunity • Profitability-Driven Enterprise • Solid global sales growth drives sustainable profitability • 2008 revenues: $54 M (unaudited); 46% increase • 2009 guidance: $60-$62 M revenues; $0.00 - $0.02 EPS • Revenue growth + tight expense management = positive cash flow and EPS • Int

  34. Slide 34: Global Strategies to Enhance Health

    Global Strategies to Enhance Health Corporate Presentation February 9, 2009

  35. Slide 35: Senior Management Team

    Senior Management Team • Friedhelm Blobel, Ph.D., President and CEO • Gryphon Therapeutics, Hoechst Group, Boehringer Mannheim Group • Gary Titus, Chief Financial Officer • Kosan Biosciences, Nuvelo, Metabolex, IntraBiotics Pharmaceuticals, and J&J’s LifeScan Division • Hans P. Schmid, President and

Sciclone Pharmaceuticals — Proxy Contest (February 2009) on 6ix